Advertisement

Can a Mixture of Insulin and a Nonsteroidal Anti-inflammatory Drug Prolong Insulin Pump Catheter Wear Time in Adults With Type 1 Diabetes?

Published:August 06, 2022DOI:https://doi.org/10.1016/j.jcjd.2022.07.007
      Continuous subcutaneous insulin infusion sets may be worn for longer than 3 days.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Canadian Journal of Diabetes
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bonato L.
        • Taleb N.
        • Gingras V.
        • et al.
        Duration of catheter use in patients with diabetes using continuous subcutaneous insulin infusion: A review.
        Diabetes Technol Ther. 2018; 7: 506-515
        • Taleb N.
        • Messier V.
        • Ott-Braschi S.
        • Ardilouze J.L.
        • Rabasa-Lhoret R.
        Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: Results of an online survey.
        Diabetes Res Clin Pract. 2018; 144: 42-50
        • Pfützner A.
        • Sachsenheimer D.
        • Grenningloh M.
        • et al.
        Using insulin infusion sets in CSII for longer than the recommended usage time leads to a high risk for adverse events: Results from a prospective randomized crossover study.
        J Diabetes Sci Technol. 2015; 9: 1292-1298
        • Schmid V.
        • Hohberg C.
        • Borchert M.
        • Forst T.
        • Pfützner A.
        Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy---trouble starts on day 3.
        J Diabetes Sci Technol. 2010; 4: 976-982
        • Hammond P.
        • Liebl A.
        • Grunder S.
        International survey of insulin pump users: Impact of continuous subcutaneous insulin infusion therapy on glucose control and quality of life.
        Prim Care Diabetes. 2007; 1: 143-146
        • Ardilouze J.L.
        • Ménard J.
        • Gobeil Jr., F.
        • et al.
        CSII: Longer catheter usage time, a reasonable goal.
        Diabetes Sci Technol. 2016; 10: 989-990
        • Pachler C.
        • Ikeoka D.
        • Plank J.
        • et al.
        Subcutaneous adipose tissue exerts proinflammatory cytokines after minimal trauma in humans.
        Am J Physiol Endocrinol Metab. 2007; 293: E690-E696
        • Conwell L.S.
        • Pope E.
        • Artiles A.M.
        • Mohanta A.
        • Daneman A.
        • Daneman D.
        Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents.
        J Pediatr. 2008; 152: 622-628
        • Pickup J.C.
        • Yemane N.
        • Brackenridge A.
        • Pender S.
        Nonmetabolic complications of continuous subcutaneous insulin infusion: A patient survey.
        Diabetes Technol Ther. 2014; 16: 145-149
        • Guilhem I.
        • Leguerrier A.M.
        • Lecordier F.
        • Poirier J.Y.
        • Maugendre D.
        Technical risks with subcutaneous insulin infusion.
        Diabetes Metab. 2006; 32: 279-284
        • Bull H.
        • Dowd P.
        Prostaglandins, interleukins, and cutaneous inflammation.
        ImmunoMethods. 1993; 2: 219-226
        • Zhang E.
        • Cao Z.
        Tissue response to subcutaneous infusion catheter.
        J Diabetes Sci Technol. 2020; 14: 226-232
        • Kesserwan S.
        • Lewis B.E.
        • Mao L.
        • et al.
        Inflammation at site of insulin infusion diminishes glycemic control.
        J Pharm Sci. 2022; 111: 1952-1961
        • Ward W.K.
        A review of the foreign-body response to subcutaneously-implanted devices: The role of macrophages and cytokines in biofouling and fibrosis.
        J Diabetes Sci Technol. 2008; 2: 768-777
        • Mulka A.
        • Lewis B.
        • Mao L.
        • et al.
        Phenolic preservative removal from commercial insulin formulations reduces tissue inflammation while maintaining euglycemia.
        ACS Pharmacol Transl Sci. 2021; 4: 1161-1174
        • Haley R.A.
        • von Recum H.
        Localized and targeted delivery of NSAIDs for treatment of inflammation: A review.
        Exp Bio Med (Maywood). 2019; 244: 433-444
        • Jett M.
        • Ramesha C.
        • Brown C.
        • et al.
        Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat.
        J Pharmacol Exp Ther. 1999; 288: 288-297
        • Rowe C.
        • Sitch A.J.
        • Barratt J.
        • et al.
        Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease.
        Kidney Int. 2019; 96: 429-435
        • Waldenmaier D.
        • Zschornark E.
        • Buhr A.
        • Pleus S.
        • Haug C.
        • Freckmann G.
        A prospective study of insulin infusion set use for up to 7 days: Early replacement reasons and impact on glycemic control.
        Diabetes Technol Ther. 2020; 22: 734-741